

# Interim report July-September 2022

## A challenging third quarter

### Quarter July-September 2022

- ▶ Net sales amounted to SEK 125.6 (111.8) million, an increase of 12.4 percent. Adjusted for currency effects, a decrease of -8.1 percent.
- ▶ The number of instruments sold amounted to 803 (996), a decrease by 19.4 percent.
- ▶ Operating profit was SEK 3.6 (13.0) million, corresponding to an operating margin of 2.9 (11.7) percent.
- ▶ Profit for the period amounted to SEK 2.4 (7.1) million.
- ▶ Basic earnings per share amounted to SEK 0.12 (0.37) and diluted earnings per share amounted to SEK 0.12 (0.36).
- ▶ Cash flow from operating activities amounted to SEK -15.8 (10.6) million.
- ▶ Net debt on September 30 amounted to SEK 73.7 million compared to last year when it was SEK 6.5 million.
- ▶ August 4th it was announced that Annette Colin leaves the Boule Diagnostics CFO position due to family reasons.
- ▶ September 6th it was announced that Clinical Diagnostic Solutions, Inc. (CDS), a subsidiary to Boule Diagnostics AB, has been issued a Notice of Inspectional Observations (FDA Form 483) by the US Food and Drug Administration (the FDA).

| Key figures                          | Jul-Sep<br>2022 | Jul-Sep<br>2021 | Jan-Sep<br>2022 | Jan-Sep<br>2021 | Oct 21-Sep<br>22 (R12) | Oct 20-Sep<br>21 (R12) |
|--------------------------------------|-----------------|-----------------|-----------------|-----------------|------------------------|------------------------|
| Sales growth, %                      | 12.4            | 13.2            | 23.5            | 5.0             | -4.9                   | -4.9                   |
| Net sales, SEK million               | 125.6           | 111.8           | 398.9           | 323.1           | 539.2                  | 415.7                  |
| Gross margin, %                      | 40.7            | 44.7            | 40.4            | 43.6            | 40.6                   | 43.3                   |
| Operating profit (EBIT), SEK million | 3.6             | 13.0            | 18.9            | 22.2            | 32.7                   | -19.5                  |
| Operating margin (EBIT), %           | 2.9             | 11.7            | 4.7             | 6.9             | 6.1                    | -4.7                   |
| Profit after tax, SEK million        | 2.4             | 7.1             | 9.8             | 6.0             | 27.1                   | -26.6                  |
| Net debt, SEK million                | 73.7            | 6.5             | 73.7            | 6.5             | 73.7                   | 6.5                    |
| Return on equity, %                  | 0.7             | 2.7             | 3.1             | 2.2             | 8.7                    | -9.8                   |
| Net debt/EBIT (R12), times           | 2.2             | -0.3            | 2.2             | -0.3            | 2.2                    | -0.3                   |
| Diluted earnings per share, SEK      | 0.12            | 0.36            | 0.49            | 0.30            | 1.40                   | -0.33                  |

### Dynamisk graf: Net sales and EBIT, rolling 12 months

Q4 2020 incl. a write-down of intangible assets of SEK 40 million.

NEXT 